Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 8:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: High dose levodopa Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

NCT02240030
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301 Low Dose, CVT-301 High Dose, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
55
States / cities
Scottsdale, Arizona • Fresno, California • Fullerton, California + 47 more
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Sep 24, 2026, 8:57 PM EDT
Completed Phase 3 Interventional Results available

Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

NCT02242487
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 86 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
55
States / cities
Scottsdale, Arizona • Fresno, California • Fullerton, California + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 24, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Results available

High and Low Dose Carbidopa Treatment of Parkinson's Disease

NCT01399905
View directory record Official record
Conditions
Parkinson's Disease
Interventions
carbidopa
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
35 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 8, 2020 · Synced Sep 24, 2026, 8:57 PM EDT
Completed Phase 4 Interventional Results available

Effect of L-dopa In Subacute Back Pain Population

NCT01951105
View directory record Official record
Conditions
Sub-acute Back Pain
Interventions
Naproxen, Carbidopa/Levodopa, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 24, 2026, 8:57 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

NCT03781167
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 24, 2026, 8:57 PM EDT
Not yet recruiting Phase 4 Interventional

Gastrointestinal Dopamine Decarboxylase and Levodopa Pharmacokinetics

NCT07793461
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Levodopa (L-dopa)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 24, 2026, 8:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Dopamine on Diabetic Retinopathy

NCT02706977
View directory record Official record
Conditions
Diabetes
Interventions
Low Dose Sinemet CR, High Dose Sinemet CR, RETeval Electroretinogram (ERG) Testing, Contrast Sensitivity Testing, Visual Acuity Testing
Drug · Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 24, 2026, 8:57 PM EDT
Terminated Phase 4 Interventional Results available

L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults

NCT03761030
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia, Depression
Interventions
L-DOPA, Placebo Oral Tablet
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 24, 2026, 8:57 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

NCT01474421
View directory record Official record
Conditions
Dyskinesias, Drug-induced
Interventions
AQW051, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years to 85 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Sacramento, California • Manhasset, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Sep 24, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Results available

New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

NCT00001849
View directory record Official record
Conditions
Cushing Syndrome, Endocrine Disease
Interventions
Pentetreotide, 18F-DOPA, CT scan, MRI, 18-FDG
Drug · Device
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 90 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 24, 2026, 8:57 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)

NCT01397422
View directory record Official record
Conditions
Dyskinesia, Levodopa Induced Dyskinesia, Parkinson's Disease
Interventions
ADS-5102 (extended release amantadine HCl)
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Sun City, Arizona • Fountain Valley, California • Long Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 24, 2026, 8:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets

NCT02812394
View directory record Official record
Conditions
Parkinson Disease
Interventions
CVT-301 (Dose Level 1), CVT-301 (Dose Level 2), Sinemet®
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
25 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 24, 2026, 8:57 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

NCT07432958
View directory record Official record
Conditions
Parkinson Disease
Interventions
AP-472, Placebo
Drug · Other
Lead sponsor
Appello Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Little Rock, Arkansas • Carlsbad, California • Los Alamitos, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 24, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Medications for Stopping Cocaine Dependence and Preventing Relapse

NCT00218023
View directory record Official record
Conditions
Cocaine Abuse, Cocaine-Related Disorders
Interventions
Modafinil, Levodopa/Carbidopa, Naltrexone HCl, Placebo, Motivational Interviewing (MI), Contingency management (CM), Cognitive-Behavioral Therapy (CBT)
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Sep 24, 2026, 8:57 PM EDT
Not yet recruiting Phase 1 Interventional

AAV2-hAADC for Parkinson's Disease (PDCS-01)

NCT07267065
View directory record Official record
Conditions
Parkinson's Disease (PD), Early Onset Parkinson Disease
Interventions
AAV2-hAADC
Drug
Lead sponsor
Krzysztof Bankiewicz
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 24, 2026, 8:57 PM EDT
Recruiting Not applicable Interventional

Real-Time Levodopa Level Monitoring in Parkinson Disease

NCT04735627
View directory record Official record
Conditions
Parkinson Disease
Interventions
Levodopameter
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 24, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Results available

Extension, Carbidopa-levodopa in Neovascular Age-related Macular Degeneration (AMD)

NCT03197493
View directory record Official record
Conditions
Macula; Degeneration, Retina
Interventions
carbidopa-levodopa 25-100 mg
Drug
Lead sponsor
Snyder, Robert W., M.D., Ph.D., P.C.
Individual
Eligibility
50 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 24, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Results available

Cognitive Remediation for Cocaine Dependence

NCT01393457
View directory record Official record
Conditions
Cocaine Dependence
Interventions
levodopa/carbidopa, Ropinirole 2 mg/d, Placebo, Ropinirole 4 mg/d
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 24, 2026, 8:57 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia

NCT00789672
View directory record Official record
Conditions
Amblyopia
Interventions
levodopa/carbidopa, patching
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
8 Years to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 24, 2026, 8:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Levodopa Response and Gut Microbiome in Patients With Parkinson's Disease

NCT04956939
View directory record Official record
Conditions
Parkinson Disease
Interventions
Low dose levodopa, High dose levodopa
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 6, 2022 · Synced Sep 24, 2026, 8:57 PM EDT